摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-氨基-N,4-二甲基苯甲酰胺 | 54884-19-4

中文名称
3-氨基-N,4-二甲基苯甲酰胺
中文别名
——
英文名称
3-amino-4-methylbenzoic acid methylamide
英文别名
N-methyl-3-amino-4-methylbenzamide;3-amino-N,4dimethylbenzamide;3-amino-4,N-dimethyl-benzamide;2-methyl-5-methylcarboxamido-aniline;3-amino-4-methyl-N-methylbenzamide;compound 2A;3-amino-N,4-dimethylbenzamide
3-氨基-N,4-二甲基苯甲酰胺化学式
CAS
54884-19-4
化学式
C9H12N2O
mdl
MFCD09045349
分子量
164.207
InChiKey
NXFCCUBWWTWZGE-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    325.0±35.0 °C(Predicted)
  • 密度:
    1.106±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.1
  • 重原子数:
    12
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.222
  • 拓扑面积:
    55.1
  • 氢给体数:
    2
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2924299090

SDS

SDS:367d0327aeef6cb9b2031a53041d4467
查看

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 3-Amino-N,4-Dimethylbenzamide
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances



SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Acute toxicity, Oral (Category 3), H301
Eye irritation (Category 2), H319
Skin sensitisation (Category 1), H317
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
T Toxic R25
R43
R36
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Danger
Hazard statement(s)
H301 Toxic if swallowed.
H317 May cause an allergic skin reaction.
H319 Causes serious eye irritation.
Precautionary statement(s)
P280 Wear protective gloves.
P301 + P310 IF SWALLOWED: Immediately call a POISON CENTER or doctor/
physician.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
Supplemental Hazard none
Statements
Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients
Substances
Molecular weight : 164,21 g/mol
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
3-Amino-N,4-Dimethylbenzamide
Acute Tox. 3; Eye Irrit. 2; Skin <= 100 %
Sens. 1; H301, H317, H319
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
3-Amino-N,4-Dimethylbenzamide
T, R25R43R36 <= 100 %
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Take victim immediately to hospital. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
No data available

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Nature of decomposition products not known.
Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.
Further information
No data available

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Wear respiratory protection. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Storage class (TRGS 510): Non-combustible, acute toxic Cat.3 / toxic hazardous materials or hazardous
materials causing chronic effects
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Avoid contact with skin, eyes and clothing. Wash hands before breaks and immediately after handling
the product.
Personal protective equipment
Eye/face protection
Face shield and safety glasses Use equipment for eye protection tested and approved under
appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face particle
respirator type N99 (US) or type P2 (EN 143) respirator cartridges as a backup to engineering
controls. If the respirator is the sole means of protection, use a full-face supplied air respirator. Use
respirators and components tested and approved under appropriate government standards such
as NIOSH (US) or CEN (EU).
Control of environmental exposure
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour No data available
c) Odour Threshold No data available
d) pH No data available
e) Melting point/freezing No data available
point
f) Initial boiling point and No data available
boiling range
g) Flash point No data available
h) Evaporation rate No data available
i) Flammability (solid, gas) No data available
j) Upper/lower No data available
flammability or
explosive limits
k) Vapour pressure No data available
l) Vapour density No data available
m) Relative density No data available
n) Water solubility No data available
o) Partition coefficient: n- No data available
octanol/water
p) Auto-ignition No data available
temperature
q) Decomposition No data available
temperature
r) Viscosity No data available
s) Explosive properties No data available
t) Oxidizing properties No data available
Other safety information
No data available

SECTION 10: Stability and reactivity
Reactivity
No data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
No data available
Conditions to avoid
No data available
Incompatible materials
No data available
Hazardous decomposition products
In the event of fire: see section 5

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
No data available
Skin corrosion/irritation
No data available
Serious eye damage/eye irritation
No data available
Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
No data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: Not available

SECTION 12: Ecological information
Toxicity
No data available
Persistence and degradability
No data available
Bioaccumulative potential
No data available
Mobility in soil
No data available
Results of PBT and vPvB assessment
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
Other adverse effects
No data available

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

SECTION 14: Transport information
UN number
ADR/RID: 2811 IMDG: 2811 IATA: 2811
UN proper shipping name
ADR/RID: TOXIC SOLID, ORGANIC, N.O.S. (3-Amino-N,4-Dimethylbenzamide)
IMDG: TOXIC SOLID, ORGANIC, N.O.S. (3-Amino-N,4-Dimethylbenzamide)
IATA: Toxic solid, organic, n.o.s. (3-Amino-N,4-Dimethylbenzamide)
Transport hazard class(es)
ADR/RID: 6.1 IMDG: 6.1 IATA: 6.1
Packaging group
ADR/RID: III IMDG: III IATA: III
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
No data available

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
No data available
Chemical Safety Assessment
For this product a chemical safety assessment was not carried out

SECTION 16: Other information
Full text of H-Statements referred to under sections 2 and 3.
Acute Tox. Acute toxicity
Eye Irrit. Eye irritation
H301 Toxic if swallowed.
H317 May cause an allergic skin reaction.
H319 Causes serious eye irritation.
Skin Sens. Skin sensitisation
Full text of R-phrases referred to under sections 2 and 3
T Toxic
R25 Toxic if swallowed.
R36 Irritating to eyes.
R43 May cause sensitisation by skin contact.
Further information
Copyright 2014 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
    N-甲基-3-硝基-4-甲基苯甲酰胺 N-methyl-3-nitro-4-methylbenzamide 329940-36-5 C9H10N2O3 194.19
    3-氨基-4-甲基苯甲酸 3-amino-p-toluic acid 2458-12-0 C8H9NO2 151.165
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    —— 5-amino-2-bromo-N,4-dimethylbenzamide 745078-00-6 C9H11BrN2O 243.103

反应信息

  • 作为反应物:
    描述:
    3-氨基-N,4-二甲基苯甲酰胺吡啶 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下, 以 二甲基亚砜N,N-二甲基甲酰胺 为溶剂, 生成
    参考文献:
    名称:
    的发现Ñ环丙基-4-甲基-3- [6-(4-甲基哌嗪-1-基)-4-氧喹唑啉-3(4 ħ) -基]苯甲酰胺(AZD6703),临床p38αMAP激酶抑制剂为炎性疾病的治疗
    摘要:
    已经确定了新颖,有效和选择性的喹唑啉酮系列的p38αMAP激酶抑制剂。为解决水溶性差和血浆蛋白结合力高以及嵌入的苯胺功能性问题而设计的修饰方法导致了临床候选N-环丙基-4-甲基-3- [6-(4-甲基哌嗪-1-基)的鉴定)-4-氧代喹唑啉-3(4 H)-基]苯甲酰胺(AZD6703)。通过了解X射线晶体学研究的结合模式来指导优化,该研究表明,随着抑制剂尺寸的减小,从DFG的“出”转变为DFG的“入”,改善了整体性能。
    DOI:
    10.1016/j.bmcl.2012.04.116
  • 作为产物:
    描述:
    4-甲基-3-硝基苯甲酸草酰氯 、 palladium 10% on activated carbon 、 氢气三乙胺N,N-二甲基甲酰胺 作用下, 以 乙醇二氯甲烷 为溶剂, 生成 3-氨基-N,4-二甲基苯甲酰胺
    参考文献:
    名称:
    的发现Ñ环丙基-4-甲基-3- [6-(4-甲基哌嗪-1-基)-4-氧喹唑啉-3(4 ħ) -基]苯甲酰胺(AZD6703),临床p38αMAP激酶抑制剂为炎性疾病的治疗
    摘要:
    已经确定了新颖,有效和选择性的喹唑啉酮系列的p38αMAP激酶抑制剂。为解决水溶性差和血浆蛋白结合力高以及嵌入的苯胺功能性问题而设计的修饰方法导致了临床候选N-环丙基-4-甲基-3- [6-(4-甲基哌嗪-1-基)的鉴定)-4-氧代喹唑啉-3(4 H)-基]苯甲酰胺(AZD6703)。通过了解X射线晶体学研究的结合模式来指导优化,该研究表明,随着抑制剂尺寸的减小,从DFG的“出”转变为DFG的“入”,改善了整体性能。
    DOI:
    10.1016/j.bmcl.2012.04.116
点击查看最新优质反应信息

文献信息

  • [EN] ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN<br/>[FR] DÉRIVÉS D'ARYLCARBOXAMIDE EN TANT QU'INHIBITEURS DE CANAL SODIQUE POUR LE TRAITEMENT DE LA DOULEUR
    申请人:AMGEN INC
    公开号:WO2011103196A1
    公开(公告)日:2011-08-25
    The present invention provides compounds that are inhibitors of voltage-gated sodium channels (Nav), in particular Nav 1.7, and are therefore useful for the treatment of diseases treatable by inhibition of these channels, in particular, chronic pain disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    本发明提供了一种抑制电压门控钠通道(Nav)的化合物,特别是Nav 1.7,因此适用于治疗通过抑制这些通道可治疗的疾病,特别是慢性疼痛疾病。还提供了含有这种化合物的药物组合物以及制备这种化合物的方法。
  • [EN] NEW SUBSTITUTED CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS<br/>[FR] NOUVEAUX DÉRIVÉS DE CYANOINDOLINE UTILISÉS COMME INHIBITEURS DE NIK
    申请人:JANSSEN PHARMACEUTICA NV
    公开号:WO2017125530A1
    公开(公告)日:2017-07-27
    The present invention relates to pharmaceutical agents of formula (I) useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF- KB-inducing kinase (NIK - also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.
    本发明涉及一种公式(I)的药物制剂,用于治疗和/或预防哺乳动物中的疾病,特别是用于治疗癌症、炎症性疾病、代谢性疾病和自身免疫性疾病的NF-KB诱导激酶(NIK,也称为MAP3K14)的抑制剂。该发明还涉及包含这些化合物的药物组合物,以及利用这些化合物或药物组合物预防或治疗癌症、炎症性疾病、包括肥胖和糖尿病在内的代谢性疾病以及自身免疫性疾病的用途。
  • [EN] PHENYL-ANILINE SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS KINASE INHIBITORS<br/>[FR] COMPOSES BICYCLIQUES A SUBSTITUTION PHENYL-ANILINE UTILISES COMME INHIBITEUR DE LA KINASE
    申请人:BRISTOL MYERS SQUIBB CO
    公开号:WO2005042537A1
    公开(公告)日:2005-05-12
    Compounds having the formula (I), and pharmaceutically acceptable salts, prodrugs, and solvates thereof, are useful as kinase inhibitors, wherein R, R1 , R2, R5, R6a, R6b, J, K, X and Z are as described in the specification.
    具有化学式(I)的化合物,以及其药学上可接受的盐、前药和溶剂化合物,可用作激酶抑制剂,其中R、R1、R2、R5、R6a、R6b、J、K、X和Z如规范中所述。
  • Process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors
    申请人:Chen Bang-Chi
    公开号:US20050176965A1
    公开(公告)日:2005-08-11
    The invention is directed to processes for preparing 2-aminothiazole-5-carboxamides of formula I wherein R 1 , R 2 , R 3 , R 4 and R 5 are as defined as set forth in the specification herein.
    这项发明涉及制备式I的2-氨基噻唑-5-羧酰胺的过程 其中R1、R2、R3、R4和R5如本规范中所定义。
  • [EN] PYRAZOLO-PYRIMIDINE ANILINE COMPOUNDS<br/>[FR] COMPOSES DE PYRAZOLO-PYRIMIDINE ANILINE
    申请人:BRISTOL MYERS SQUIBB CO
    公开号:WO2003099820A1
    公开(公告)日:2003-12-04
    Compounds having the formula (I), where all substituents are as defined herein, and pharmaceutically acceptable salts, prodrugs, and solvates thereof, are useful as kinase inhibitors.
    具有式(I)的化合物,其中所有取代基如本文所定义,并且其药用可接受的盐、前药和溶剂化合物对于作为激酶抑制剂是有用的。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐